BioMimetic Therapeutics  

Company News

Medovex Corporation Adds John Blank, M.D. to Board of Directors
Medovex (April 30, 2015)
FDA rejection of Augment graft improves future for smaller companies (August 12, 2013)
Medtech M&A on course for the worst year in a decade (July 25, 2013)

Displaying 10 out of a possible 225 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile 01 MAR 2013: Wright Medical Group acquired BioMimetic Therapeutics for $380m or $12.97 per share, based on Wright’s closing stock price on 16 NOV 2012.

BioMimetic Therapeutics (BMTI) was a Tennessee based biotechnology company focused on development & marketing of clinically proven products to promote the healing of musculoskeletal injuries & diseases, including therapies for orthopaedic & sports medicine applications.
Listed or Private Company Listed
Company Classification Specialty (Pharma); Biotechnology; MedTech
Country USA
Company Website
Technology Platform Profile Regenerative technology:
Promotes tissue healing and regeneration by combining rhPDGF-BB with tissue specific matrices, when appropriate.
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
19/11/2012 19 Nov: Wright Medical plans to buy company for $190m in cash and stock, plus an additional $190m if the FDA approves BioMimetic's Augment Bone Graft and if products reach certain sales targets; deal completion due Q1'13. Loewen Ondaatje McCutcheon maintains "buy" rating with a price target of $7.50. 204 74.2% 87

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
BioMimetic Therapeutics 1 12


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now